CIPLA AUSTRALIA PTY LTD — Lenalidomide Importer Profile
Pharmaceutical Importer · #14 buyer for Lenalidomide · $398.3K import value · 10 shipments · AUSTRALIA · DGFT Verified
CIPLA AUSTRALIA PTY LTD is the #14 importer of Lenalidomide from India with $398.3K in import value and 10 verified shipments. CIPLA AUSTRALIA PTY LTD holds a 0.1% market share in Lenalidomide imports based in AUSTRALIA. The company sources from 1 verified supplier across 4 formulations shipped to 1 country. Overall, CIPLA AUSTRALIA PTY LTD imports 3 pharmaceutical products worth $2.9M across 2 therapeutic categories.
CIPLA AUSTRALIA PTY LTD — Lenalidomide Import Profile: Suppliers, Formulations & Sources
Who Actually Supplies Lenalidomide to CIPLA AUSTRALIA PTY LTD?
Verified from 10 customs shipment records
| Supplier | Value | Shipments | % Share |
|---|---|---|---|
| CIPLA LIMITED | $398.3K | 10 | 100.0% |
CIPLA AUSTRALIA PTY LTD sources Lenalidomide from 1 verified Indian supplier based on 10 customs records. The primary supplier is CIPLA LIMITED accounting for 100.0% of imports.
How Does CIPLA AUSTRALIA PTY LTD Compare to Nearest Lenalidomide Importers?
Buyers ranked immediately above and below #14 by import value
| # | Buyer | Country | Import Value | Shipments | Avg/Shipment |
|---|---|---|---|---|---|
| 12 | PHARMIS SARL | MOROCCO | $1.1M | 21 | $50.0K |
| 6 | AUROBINDO PHARMA USA INC | UNITED STATES | $650.0K | 13 | $50.0K |
| 14 | CIPLA AUSTRALIA PTY LTD ★ | AUSTRALIA | $500.0K | 10 | $50.0K |
| 2 | SUN PHARMACEUTICAL INDUSTRIESINC. | UNITED STATES | $400.0K | 8 | $50.0K |
| 1 | SUN PHARMACEUTICAL INDUSTRIES,INC. | UNITED STATES | $350.0K | 7 | $50.0K |
CIPLA AUSTRALIA PTY LTD ranks #14 among 557 Lenalidomide importers from India. Average shipment value of $50.0K compared to the market average of $20.6K. The closest competitors by value are PHARMIS SARL and AUROBINDO PHARMA USA INC.
Where Does CIPLA AUSTRALIA PTY LTD Import Lenalidomide To?
Destination countries from 10 verified shipments
| Country | Value | Shipments | Share |
|---|---|---|---|
| AUSTRALIA | $398.3K | 10 | 100.0% |
CIPLA AUSTRALIA PTY LTD imports Lenalidomide to 1 country. The primary destination is AUSTRALIA receiving 100.0% of shipments worth $398.3K.
What Lenalidomide Formulations Does CIPLA AUSTRALIA PTY LTD Import?
| Formulation | Value | Shipments |
|---|---|---|
| CIPLA LENALIDOMIDE 10MG CAPSULES (LENALI | $116.7K | 3 |
| CIPLA LENALIDOMIDE 15MG CAPSULES (LENALI | $114.0K | 3 |
| CIPLA LENALIDOMIDE 5MG CAPSULES (LENALID | $96.5K | 2 |
| CIPLA LENALIDOMIDE 25MG CAPSULES (LENALI | $71.1K | 2 |
CIPLA AUSTRALIA PTY LTD imports 4 distinct Lenalidomide formulations from India. The top formulation is CIPLA LENALIDOMIDE 10MG CAPSULES (LENALI with 3 shipments worth $116.7K.
Regulatory Requirements: Importing Lenalidomide into Australia
What CIPLA AUSTRALIA PTY LTD and other importers must comply with to import Lenalidomide from India
Regulatory Authority
Therapeutic Goods Administration (TGA)
Approval Process for Generic Lenalidomide
Application for registration on the Australian Register of Therapeutic Goods (ARTG). Generic pathway requires bioequivalence and quality data per TGA guidelines.
Typical timeline: 10–14 months
GMP Requirements
TGA GMP clearance; PIC/S-aligned inspection of overseas manufacturing facilities
Import Licence & Documentation
TGA manufacturing licence or sponsor licence for import; GMP clearance for each manufacturing site
Labeling & Packaging
Australian-specific labeling per TGO 91/92; English language; AUST R number
Note: TGA participates in PIC/S mutual recognition — PIC/S GMP certificate from India may expedite clearance.
Regulatory information is provided for general reference based on publicly available TGA guidelines for pharmaceutical imports. Requirements may vary by specific drug formulation, dosage form, and therapeutic classification. Importers should consult directly with TGA or qualified regulatory affairs professionals for case-specific guidance.
Who Are the Top Buyers of Lenalidomide from India and How Much Does CIPLA AUSTRALIA PTY LTD Import?
India exported $11.5M worth of Lenalidomide through 2,724 shipments from 237 suppliers to 122 countries, serving 557 buyers globally. CIPLA AUSTRALIA PTY LTD imports $398.3K of this total, accounting for 0.1% of India's Lenalidomide exports with 10 shipments from AUSTRALIA. This is verified from 10 customs shipment records covering 4 distinct formulations.
What Is the Average Order Value for CIPLA AUSTRALIA PTY LTD's Lenalidomide Imports?
CIPLA AUSTRALIA PTY LTD's average Lenalidomide order value is $39.8K per consignment, based on 10 shipments totaling $398.3K. CIPLA AUSTRALIA PTY LTD is based in AUSTRALIA and ranks #14 among all Lenalidomide importers from India by value. The company sources from 1 verified supplier in India.
Who Supplies Lenalidomide to CIPLA AUSTRALIA PTY LTD?
CIPLA AUSTRALIA PTY LTD sources Lenalidomide from 1 verified Indian supplier: CIPLA LIMITED ($398.3K, 100.0%). This is based on 10 customs records.
How Does CIPLA AUSTRALIA PTY LTD Compare to Other Lenalidomide Importers?
CIPLA AUSTRALIA PTY LTD ranks #14 among 557 Lenalidomide importers from India with a 0.1% market share. The top 3 importers are YUSEN LOGISTICS BENELUX BELGIUM ($2.5M), BROCACEF NL HUB ($2.0M), AUROBINDO PHARMA USA., INC, ($1.9M). CIPLA AUSTRALIA PTY LTD processed 10 shipments from AUSTRALIA.
About CIPLA AUSTRALIA PTY LTD
CIPLA AUSTRALIA PTY LTD imports 3 products worth $2.9M. Beyond Lenalidomide, top products include Fluticasone, Salmeterol. View the complete CIPLA AUSTRALIA PTY LTD profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Lenalidomide — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- European Medicines Agency
- WHO Essential Medicines
- Invest India — Pharma Sector
- India Trade Statistics (DGFT)
Verify import regulations and drug registration requirements with the agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Lenalidomide shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature and HS code classification.
- 2.Buyer Identification: CIPLA AUSTRALIA PTY LTD matched across shipments using first-3-word normalization of the consignee field, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort buyer rankings.
- 4.Market Share: Calculated as CIPLA AUSTRALIA PTY LTD's capped import value divided by total capped export value for Lenalidomide across all Indian exporters.
- 5.Verified Records: This page is backed by 10 individual customs records matching CIPLA AUSTRALIA PTY LTD importing Lenalidomide, covering 4 formulations from 1 verified supplier.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 122+ countries, 557+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Lenalidomide Import Data for CIPLA AUSTRALIA PTY LTD
Access order-level details, pricing data, supplier connections, and competitive analysis for CIPLA AUSTRALIA PTY LTD's Lenalidomide imports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
CIPLA AUSTRALIA PTY LTD
Full Company Profile →
3 products · $2.9M total trade · 2 categories
CIPLA AUSTRALIA PTY LTD × Lenalidomide
Verified from customs records
Company Overview
Top Products by CIPLA AUSTRALIA PTY LTD
Related Analysis
Need Detailed Import Data?
Access shipment-level records, supplier contacts, and formulation details for CIPLA AUSTRALIA PTY LTD.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Lenalidomide. For current order-level data, contact TransData Nexus.